SPORE in Cervical Cancer

宫颈癌中的孢子

• 批准号: 7676323
• 负责人: TZYY-CHOOU WU
• 金额: $ 116.5万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7676323
• 关键词: Address; Antigens; Area; Basic Science; Bioinformatics; Biological Markers; Biometry; Carcinoma; Cervical; Clinical; Clinical Trials; Combined Vaccines; DNA; DNA Vaccines; Detection; Detox; Development; Diagnosis; Disease Progression; Doctor of Medicine; Doctor of Philosophy; Evaluation Research; Funding; Goals; HIV; HIV Seropositivity; Human; Human Papillomavirus; Human papillomavirus 16; Immune response; Incidence; India; Individual; Infection; Intervention; Lesion; Malignant neoplasm of cervix uteri; Morbidity - disease rate; Nature; Numbers; Oncogenic; Outcome; Pan Genus; Pathogenesis; Pathology; Patients; Prevention; Preventive; Principal Investigator; Program Description; Program Development; Research; Research Personnel; Research Project Grants; Risk; Risk Assessment; Rural; Rural Community; Scientific Advances and Accomplishments; Screening procedure; Specialized Program of Research Excellence; Squamous intraepithelial lesion; T-Lymphocyte; Techniques; Testing; TimeLine; Tissues; Translational Research; Translations; Universities; Vaccination; Vaccines; antiangiogenesis therapy; anticancer research; base; cancer immunotherapy; carcinogenesis; career; cell mediated immune response; innovation; interest; intraepithelial; medical schools; mortality; multidisciplinary; novel; programs; protective effect; response; therapeutic vaccine; tumor progression; Address; Antigens; Area; Basic Science; Bioinformatics; Biological Markers; Biometry; Carcinoma; Cervical; Clinical; Clinical Trials; Combined Vaccines; DNA; DNA Vaccines; Detection; Detox; Development; Diagnosis; Disease Progression; Doctor of Medicine; Doctor of Philosophy; Evaluation Research; Funding; Goals; HIV; HIV Seropositivity; Human; Human Papillomavirus; Human papillomavirus 16; Immune response; Incidence; India; Individual; Infection; Intervention; Lesion; Malignant neoplasm of cervix uteri; Morbidity - disease rate; Nature; Numbers; Oncogenic; Outcome; Pan Genus; Pathogenesis; Pathology; Patients; Prevention; Preventive; Principal Investigator; Program Description; Program Development; Research; Research Personnel; Research Project Grants; Risk; Risk Assessment; Rural; Rural Community; Scientific Advances and Accomplishments; Screening procedure; Specialized Program of Research Excellence; Squamous intraepithelial lesion; T-Lymphocyte; Techniques; Testing; TimeLine; Tissues; Translational Research; Translations; Universities; Vaccination; Vaccines; antiangiogenesis therapy; anticancer research; base; cancer immunotherapy; carcinogenesis; career; cell mediated immune response; innovation; interest; intraepithelial; medical schools; mortality; multidisciplinary; novel; programs; protective effect; response; therapeutic vaccine; tumor progression

DESCRIPTION (provided by applicant): This application for a Specialized Program of Research Excellence (SPORE) in Cervical Cancer at The Johns Hopkins University School of Medicine brings together a highly interactive, multidisciplinary, and interinstitutional program of translational research in cervical cancer. The SPORE includes six integrated projects spanning the fields of screening, diagnosis, prevention and treatment. Project 1: Markers of progression to cervical cancer in rural India (Keerti Shah, M.D., DR.PH. and Kathleen Cho, M.D). Project 2, Identification of molecular markers for cervical cancer progression (Kathleen Cho, M.D. and Carolyn Johnston, M.D.). Project 3, Development of a pan-oncogenic HPV preventive vaccine (Richard Roden, Ph.D. and Raphael Viscidi, M.D). Project 4, Human immunological responses to chimeric Ll/L2-E2- E7 VLP (Clayton Harro, M.D., Sc.M., Drew Pardoll, M.D., Ph.D., and Richard Roden, Ph.D.). Project 5, Vaccination with SigIE7(detox)/HSP70 DNA to treat patients with HPV-associated high grade squamous intraepithelial lesions with or without HIV (Drew Pardoll, M.D., Ph.D., Cornelia Trimble, M.D., and T.-C. Wu, M.D., Ph.D.). Project 6, Combination of antigen-specific cancer immunotherapy and anti-angiogenesis to treat patients with advanced cervical cancer (T.-C. Wu, M.D., Ph.D. and Debbie Armstrong, M.D.) These six research projects are supported by three cores. Core 1, Tissue/Pathology (Robert J. Kurman, M. D. and Fredrick Montz, M.D.). Core 2, Biostatistics and Bioinformatics (Mei-Cheng Wang, Ph.D.) The SPORE also includes a major Developmental Research Program (Drew Pardoll, M.D., Ph.D. and T.-C. Wu) for rapid funding of novel ideas and a Career Development Program (T.-C. Wu, M.D., Ph.D. and Fredrick Montz, M.D.) to facilitate career development of individuals with an interest in translational cervical cancer research.

描述（申请人提供）：本申请在约翰·霍普金斯大学医学院的宫颈癌专门研究卓越研究（孢子）的申请中，汇集了一项高度互动，多学科和宫颈癌转化研究间的跨学科计划。 孢子包括六个跨越筛查，诊断，预防和治疗领域的综合项目。 项目1：印度农村地区宫颈癌的进展标记（Keerti Shah，M.D。，Ph.和Kathleen Cho，M.D）。 项目2，诊断宫颈癌进展的分子标记（Kathleen Cho，M.D。和Carolyn Johnston，M.D。）。项目3，开发泛生成HPV预防疫苗（Richard Roden博士和Raphael Viscidi，M.D）。 项目4，人类免疫学对嵌合LL/L2-E2-E7 VLP的反应（Clayton Harro，M.D.，SC.M.，Drew Pardoll，M.D。 项目5，SIGIE7（排毒）/HSP70 DNA疫苗接种，以治疗患有或没有HIV的HPV相关的高级鳞状上皮内病变（Drew Pardoll，M.D.，M.D.，Ph.D.，Ph.D.，Cornelia trimble，M.D。和T.-C。Wu，M.D. 项目6，抗原特异性癌症免疫疗法和抗血管生成，以治疗晚期宫颈癌患者（T.-C。Wu，M.D。，Ph.D.和Debbie Armstrong，M.D。）这六个研究项目得到了三个核心的支持。 核心1，组织/病理学（Robert J. Kurman，M。D.和Fredrick Montz，M.D。）。 核心2，生物统计学和生物信息学（Mei-Cheng Wang，Ph.D.）孢子还包括一项主要的发展研究计划（Drew Pardoll，M.D。，Ph.D。和T.-C。Wu），以快速资助新颖的想法和职业发展计划（T.-C。Wu，M.D.，Ph.D。，Ph.D.和Fredrick M.D.宫颈癌研究。